Edition:
India

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

1.81USD
1:30am IST
Change (% chg)

$-0.01 (-0.55%)
Prev Close
$1.82
Open
$1.85
Day's High
$1.85
Day's Low
$1.79
Volume
21,717
Avg. Vol
83,436
52-wk High
$4.38
52-wk Low
$1.24

Latest Key Developments (Source: Significant Developments)

Cidara Therapeutics Says Rezafungin Achieved Positive Topline Results In Its Phase 2 Strive B Trial
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Cidara Therapeutics Inc ::CIDARA PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.REZAFUNGIN ACHIEVED POSITIVE TOPLINE RESULTS IN ITS PHASE 2 STRIVE B TRIAL.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $44.6 MILLION AS OF JUNE 30, 2019.QTRLY LOSS PER SHARE $0.49.Q2 EARNINGS PER SHARE VIEW $-0.57 -- REFINITIV IBES DATA.  Full Article

Cidara Reports Fourth Quarter And Full Year 2018 Financial Results
Friday, 1 Mar 2019 

Feb 28 (Reuters) - Cidara Therapeutics Inc ::CIDARA PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.CIDARA THERAPEUTICS INC QTRLY NET LOSS PER SHARE $0.44.CIDARA THERAPEUTICS - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $74.6 MILLION AS OF DEC 31, 2018, VERSUS $75.3 MILLION AS OF DECEMBER 31, 2017.  Full Article

Cidara Therapeutics says May Sell Shares Of Upto $35 mln
Saturday, 17 Nov 2018 

Nov 16 (Reuters) - Cidara Therapeutics Inc ::MAY OFFER, SELL SHARES OF CO'S COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $35 MILLION FROM TIME TO TIME - SEC FILING.  Full Article

Cidara Therapeutics Qtrly Loss Per Share $0.49
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.49.CIDARA THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $88.3 MILLION AS OF SEPTEMBER 30, 2018.CIDARA THERAPEUTICS INC - FOCUSED ON INITIATING PHASE 3 RESPECT PROPHYLAXIS TRIAL IN Q1 2019.  Full Article

Cidara Therapeutics Enters Into Controlled Equity Offering
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS INC - ON NOVEMBER 8, 2018, ENTERED INTO A CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING.CIDARA THERAPEUTICS - MAY OFFER, SELL, FROM TIME TO TIME SHARES OF CO'S COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $35.0 MILLION.  Full Article

Cidara Therapeutics Files For Mixed Shelf Of Up To $150 Mln
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING.  Full Article

Cidara Therapeutics Says On Sept. 6, Increased Authorized Size Of Board Members From 6 To 7
Thursday, 13 Sep 2018 

Sept 12 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS - ON SEPT. 6, UPON RECOMMENDATION OF BOARD, APPROVED INCREASE IN AUTHORIZED SIZE FROM 6 TO 7 BOARD MEMBERS - SEC FILING.  Full Article

Cidara Therapeutics Says Matthew Onaitis Resigned As CFO
Saturday, 18 Aug 2018 

Aug 17 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS SAYS EFFECTIVE AUG 17, MATTHEW ONAITIS RESIGNED FROM POSITIONS AS CFO - SEC FILING.  Full Article

Cidara Announces Stock And Warrants Offering Worth $120 Mln
Monday, 21 May 2018 

May 21 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS ANNOUNCES OFFERING OF COMMON STOCK AND WARRANTS.CIDARA THERAPEUTICS - ENTERED SECURITIES PURCHASE DEAL WITH CERTAIN INVESTORS PROVIDING FOR PURCHASE, SALE OF UP TO $120 MILLION OF ITS COMMON STOCK.CIDARA THERAPEUTICS INC - CIDARA WILL OFFER ABOUT 10.6 MILLION SHARES OF COMMON STOCK IN FIRST CLOSING OF OFFERING AT $4.70 PER SHARE.CIDARA THERAPEUTICS - ENTERED SECURITIES PURCHASE AGREEMENT FOR PURCHASE &SALE, OF UP TO AGGREGATE OF $120.0 MILLION OF ITS COMMON STOCK, IN 3 CLOSINGS.CIDARA - ALSO SELLING TO MAJOR PURCHASERS WARRANTS, AT $0.125/SHARE SUBJECT TO EACH SUCH WARRANT, TO PURCHASE AGGREGATE 12.5 MILLION SHARES OF STOCK.  Full Article

Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin
Monday, 19 Mar 2018 

March 19 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN.CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN.CIDARA THERAPEUTICS INC - ‍PHASE 3 STUDIES FOR BOTH TREATMENT AND PREVENTION ON TRACK TO START MID-2018​.CIDARA THERAPEUTICS INC - PHASE 3 STUDIES FOR BOTH TREATMENT AND PREVENTION ON TRACK TO START MID-2018.CIDARA THERAPEUTICS - ‍FAVORABLE SAFETY,TOLERABILITY,EFFICACY OBSERVED IN ONCE-WEEKLY ECHINOCANDIN FOR DIFFICULT-TO-TREAT INVASIVE FUNGAL INFECTIONS​.CIDARA THERAPEUTICS INC - ‍STRIVE MET ALL OF ITS PRIMARY OBJECTIVES​.CIDARA THERAPEUTICS INC - ‍THERE WERE NO CONCERNING TRENDS IN ADVERSE EVENTS OBSERVED​.CIDARA THERAPEUTICS-THERE WERE 2 SERIOUS ADVERSE EVENTS POSSIBLY RELATED TO STUDY DRUG: ONE IN GROUP 2, ONE IN GROUP 3; BOTH PATIENTS FULLY RECOVERED​.CIDARA THERAPEUTICS INC - ‍ PHASE 3 RESPECT PROPHYLAXIS TRIAL EXPECTED TO PRODUCE AN INTERIM FUTILITY READ-OUT IN 2019, PROVIDE TOPLINE RESULTS IN 2020​.  Full Article